Literature DB >> 32527947

ADPKD, Tolvaptan, and Nephrolithiasis Risk.

Ewout J Hoorn1, Robert Zietse2.   

Abstract

Entities:  

Keywords:  Autosomal Dominant; Kidney Calculi; Polycystic Kidney; Tolvaptan; calcium; cyclic AMP; cystic kidney; hypercalciuria; kidney stones; kidney tubule; polycystic kidney disease; risk factors

Mesh：

Substances：

Year:  2020        PMID： 32527947      PMCID： PMC7341782          DOI： 10.2215/CJN.07610520

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  11 in total

1.  Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Authors:  Matteo Bargagli; Nasser A Dhayat; Manuel Anderegg; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Pietro Manuel Ferraro; Daniel G Fuster
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

2.  The association of nephrolithiasis and autosomal dominant polycystic kidney disease.

Authors:  V E Torres; S B Erickson; L H Smith; D M Wilson; R R Hattery; J W Segura
Journal:  Am J Kidney Dis       Date:  1988-04       Impact factor: 8.860

Review 3.  Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis.

Authors:  Wisit Cheungpasitporn; Sandro Rossetti; Keith Friend; Stephen B Erickson; John C Lieske
Journal:  J Nephrol       Date:  2015-05-29       Impact factor: 3.902

4.  Vasopressin Increases Urinary Acidification via V1a Receptors in Collecting Duct Intercalated Cells.

Authors:  Torsten Giesecke; Nina Himmerkus; Jens Leipziger; Markus Bleich; Taka-Aki Koshimizu; Michael Fähling; Alina Smorodchenko; Julia Shpak; Carolin Knappe; Julian Isermann; Niklas Ayasse; Katsumasa Kawahara; Jan Schmoranzer; Niclas Gimber; Alexander Paliege; Sebastian Bachmann; Kerim Mutig
Journal:  J Am Soc Nephrol       Date:  2019-05-16       Impact factor: 10.121

5.  Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations.

Authors:  Wisit Cheungpasitporn; Stephen B Erickson; Andrew D Rule; Felicity Enders; John C Lieske
Journal:  J Urol       Date:  2015-11-17       Impact factor: 7.450

6.  Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia.

Authors:  Roberto Tamma; Li Sun; Concetta Cuscito; Ping Lu; Michelangelo Corcelli; Jianhua Li; Graziana Colaianni; Surinder S Moonga; Adriana Di Benedetto; Maria Grano; Silvia Colucci; Tony Yuen; Maria I New; Alberta Zallone; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

7.  Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.

Authors:  José L Nishiura; Rodrigo F C A Neves; Samara R M Eloi; Susan M L F Cintra; Sergio A Ajzen; Ita P Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-01       Impact factor: 8.237

8.  Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

Authors:  Niek F Casteleijn; Jaime D Blais; Arlene B Chapman; Frank S Czerwiec; Olivier Devuyst; Eiji Higashihara; Anna M Leliveld; John Ouyang; Ronald D Perrone; Vicente E Torres; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2016-11-14       Impact factor: 8.860

9.  Hyponatremia and the risk of kidney stones: A matched case-control study in a large U.S. health system.

Authors:  Naoto Tominaga; Stephen J Fernandez; Mihriye Mete; Nawar M Shara; Joseph G Verbalis
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

10.  Role of enteroendocrine L-cells in arginine vasopressin-mediated inhibition of colonic anion secretion.

Authors:  Ramona Pais; Juraj Rievaj; Claire Meek; Gayan De Costa; Samanthie Jayamaha; R Todd Alexander; Frank Reimann; Fiona Gribble
Journal:  J Physiol       Date:  2016-04-28       Impact factor: 5.182
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.